Cited by 1,677Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells

Open access

Spranger, Stefani, Spaapen, Robbert M., Zha, Yuanyuan, Williams, Jason, Meng, Yuru, Ha, Thanh T., Gajewski, Thomas F.·2013·Science Translational Medicine

DOI 10.1126/scitranslmed.3006504PMC PMC4136707

Open this paper in CoChat — free account

Abstract

Tumor escape from immune-mediated destruction has been associated with immunosuppressive mechanisms that inhibit T cell activation. Although evidence for an active immune response, including infiltration with CD8(+) T cells, can be found in a subset of patients, those tumors are nonetheless not immunologically rejected. In the current report, we show that it is the subset of T cell-inflamed tumors that showed high expression of three defined immunosuppressive mechanisms: indoleamine-2,3-dioxygenase (IDO), PD-L1/B7-H1, and FoxP3(+) regulatory T cells (T(regs)), suggesting that these inhibitory pathways might serve as negative feedback mechanisms that followed, rather than preceded, CD8(+) T cell infiltration. Mechanistic studies in mice revealed that up-regulated expression of IDO and PD-L1, as well as recruitment of T(regs), in the tumor microenvironment depended on the presence of CD8(+) T cells. The former was driven by interferon-γ and the latter by a production of CCR4-binding chemokines along with a component of induced proliferation. Our results argue that these major immunosuppressive pathways are intrinsically driven by the immune system rather than being orchestrated by cancer cells, and imply that cancer immunotherapy approaches targeting negative regulatory immune checkpoints might be preferentially beneficial for patients with a preexisting T cell-inflamed tumor microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3006504

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137 · cited 1×
“Previous work has shown that antigen-presenting cells in the tumor microenvironment can be tolerogenic (37), and that some cytokines abundant in the tumor, such as IL-10, can inhibit dendritic cell activation and result in T cell anergy (38).”
Background
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“…has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2), and the recently U.S. Food and Drug Administration–approved agents Provenge for prostate cancer (3) and anti– CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4).”
Background
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“…has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2), and the recently U.S. Food and Drug Administration–approved agents Provenge for prostate cancer (3) and anti– CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4).”
Background
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Although direct CCL22 production by tumor cells in other cancer types also has been suggested (34), we did not detect CCL22 mRNA expression in a series of melanoma cell lines, arguing that in the melanoma context, it is likely derived from infiltrating nontumor stromal cells (13).”
Background
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · cited 1×
“Clinical strategies to counter these immunosuppressive pathways are currently being evaluated, already with encouraging early-phase clinical trial results (10–12).”
Background
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589 · cited 1×
“IDO is a tryptophanmetabolizing enzyme that has been shown to contribute to peripheral immunologic tolerance (25).”
Background
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“…in mouse models include extrinsic suppression of CD8 + effector cells by CD4 + CD25 + FoxP3 + regulatory T cells (T regs ) (6), metabolic deregulation via tryptophan catabolism by indoleamine-2,3-dioxygenase (IDO) (7), and engagement of the inhibitory receptor PD-1 by the ligand PD-L1/B7-H1 (8, 9).”
Background
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · cited 2×
“It has been speculated that clinical response to antibodies targeting the PD-L1/PD-1 interaction may end up being restricted to cases in which PD-L1 expression is associated with a CD8 + T cell infiltrate and therefore is likely blunting host immunity (32).”
Background

Show all 50 references

Sorted by citations

Items 601–700 of 1,001

Extracellular Vesicle‐Based Therapeutic Targeting of β‐Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer
Matsuda, A., Ishiguro, K., Yan, I. K., & Patel, T. C. (2019) · Hepatology Communications · doi:10.1002/hep4.1311 · Cited by 60
IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment
Li, Q., Liu, J., Fan, H., Shi, L., Deng, Y., Zhao, L., Xiang, M., Xu, Y., Jiang, X., Wang, G., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120388 · Cited by 61
Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation
Wang, J. Y., Jiang, M. W., Li, M. Y., Zhang, Z. H., Xing, Y., Ri, M., Jin, C. H., Xu, G. H., Piao, L. X., Jin, H. L., et al. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108899 · Cited by 61
Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance
Yan, J., Liu, D., Wang, J., You, W., Yang, W., Yan, S., & He, W. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101037 · Cited by 60
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers
Fumagalli, D., Wilson, T. R., Salgado, R., Lu, X., Yu, J., O'Brien, C. L., Walter, K., Huw, L., Criscitiello, C., Laïos, I., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw286 · Cited by 61
Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets
Bolen, C. R., McCord, R., Huet, S., Frampton, G. M., Bourgon, R., Jardin, F., Dartigues, P., Punnoose, E. A., Szafer‐Glusman, E., Xerri, L., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016000786 · Cited by 60
Prognostic significance of spatial immune profiles in human solid cancers
Tsujikawa, T., Mitsuda, J., Ogi, H., Miyagawa‐Hayashino, A., Konishi, E., Itoh, K., & Hirano, S. (2020) · Cancer Science · doi:10.1111/cas.14591 · Cited by 58
Sequential and Timely Combination of a Cancer Nanovaccine with Immune Checkpoint Blockade Effectively Inhibits Tumor Growth and Relapse
Kim, Y., Kang, S., Shin, H., Kim, T. W., Yu, B., Kim, J., Yoo, D., & Jon, S. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006117 · Cited by 58
Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma
Xie, Q., Zhao, Y., Pan, T., Lyu, N., Mu, L., Li, S., Shi, M.-D., Zhang, Z., Zhou, P., & Zhao, M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1181252 · Cited by 58
Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors
Shah, S. J., Ward, J. E., Bao, R., Hall, C. R., Brockstein, B., & Luke, J. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0087 · Cited by 58
Molecular mechanisms of HLA class I‐mediated immune evasion of human tumors and their role in resistance to immunotherapies
Seliger, B. (2016) · HLA · doi:10.1111/tan.12898 · Cited by 56
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
Dutoit, V., Migliorini, D., Dietrich, P., & Walker, P. R. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00256 · Cited by 59
PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies
Frydenlund, N., & Mahalingam, M. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.06.012 · Cited by 62
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level
Grenier, J. M., Yeung, S. T., & Khanna, K. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00610 · Cited by 58
New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression
Gullo, I., Oliveira, P., Athelogou, M., Gonçalves, G., Pinto, M. L., Carvalho, J., Valente, A., Pinheiro, H. C., Andrade, S., Almeida, G. M., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0836-8 · Cited by 58
N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression
Mehndiratta, S., Lin, M.-H., Wu, Y.-W., Chen, C., Wu, T.-Y., Chuang, K.-H., Chao, M., Chen, Y., Pan, S., Chen, M.-C., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111725 · Cited by 58
CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Xiao, M., Xie, L., Cao, G., Lei, S., Wang, P., Wei, Z., Luo, Y., Fang, J., Yang, X., Huang, Q., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004022 · Cited by 59
FAM family gene prediction model reveals heterogeneity, stemness and immune microenvironment of UCEC
Chi, H., Gao, X., Xia, Z., Yu, W., Yin, X., Pan, Y., Peng, G., Mao, X., Teichmann, A. T., Zhang, J., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1200335 · Cited by 57
“Previous studies have reported that high levels of CTLA-4 expression are associated with a better prognosis in UCEC patients (Spranger et al., 2013; Liu et al., 2020).”
Background
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 56
Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors
Skelton, R. A., Javed, A. A., Zheng, L., & He, J. P. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24642 · Cited by 56
Epithelial–Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression
Kolijn, K., Verhoef, E. I., Smid, M., Böttcher, R., Jenster, G. W., Debets, R., & van Leenders, G. J. L. H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3752 · Cited by 58
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 59
“Prostaglandin E2 (PGE2) and its key synthesizing enzyme cyclooxygenase 2 (COX2) can induce and recruit MDSCs in TME, and inhibition of COX2 has synergized anti-PD therapy in pre-clinical models (Li et al., 2016).”
BackgroundInfluential
Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses
Zhu, Y., Wang, X., Zhang, Y., Xu, D., Dong, J., Zhang, Z., Yi, C., Jia, H., & Yang, X. L. (2018) · Cancer Management and Research · doi:10.2147/cmar.s172719 · Cited by 57
“This seemingly conflicting result may be because tumors expressing high level of PD-L1 were more likely to be infiltrated with abundant CD8+ T-cells (Figure 2A, B), which is consistent with the new concept that tumors express PD-L1 as an adaptive resistance mechanism to an active antitumor immune response.(15,16) In a…”
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases
Angela, Y., Haferkamp, S., Weishaupt, C., Ugurel, S., Becker, J. C., Oberndörfer, F., Alar, V., Satzger, I., & Gutzmer, R. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02353-5 · Cited by 57
Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma
Keller, H. R., Zhang, X., Li, L., Schaider, H., & Wells, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.18523 · Cited by 55
Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies
Fu, R., Li, Y., Jiang, N., Ren, B., Zang, C.-Z., Liu, L., Lv, W., Li, H., Weiss, S. J., Li, Z., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131507 · Cited by 60
Determinants of resistance and response to melanoma therapy
Robertson, B. M., Fane, M. E., Weeraratna, A. T., & Rebecca, V. W. (2024) · Nature Cancer · doi:10.1038/s43018-024-00794-1 · Cited by 68
Immune modulation in advanced radiotherapies: Targeting out-of-field effects
Hanna, G. G., Coyle, V., & Prise, K. M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.007 · Cited by 56
Reducing CD73 Expression by IL1β-Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors
Chatterjee, S., Thyagarajan, K., Kesarwani, P., Song, J. H., Soloshchenko, M., Fu, J., Bailey, S. R., Vasu, C., Kraft, A. S., Paulos, C. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1450 · Cited by 58
The proteasome immunosubunits, PA28 and ER‐aminopeptidase 1 protect melanoma cells from efficient MART‐126‐35‐specific T‐cell recognition
Keller, M., Ebstein, F., Bürger, E., Textoris‐Taube, K., Gorny, X., Urban, S., Zhao, F., Dannenberg, T., Sucker, A., Keller, C., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201445243 · Cited by 54
Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer
Xie, M., Wei, J., & Xu, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00676 · Cited by 56
“It has been proposed that chemokine (CC motif) ligand 22 (CCL22), expressed by different immune cells including DCs, macrophages and so on, can induce Treg cell migration by interacting with chemokine receptors such as C-C chemokine receptor type 4 (CCR4) on Treg cells (8, 85, 86).”
Background
The clinical development of vaccines for HER2 + breast cancer: Current landscape and future perspectives
Costa, R. L. B., Soliman, H. H., & Czerniecki, B. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.005 · Cited by 56
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers
Baxter, M. A., Middleton, F., Cagney, H. P., & Petty, R. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01425-7 · Cited by 54
The tumor-nerve circuit in breast cancer
Cui, Q., Jiang, D., Zhang, Y., & Chen, C. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10095-1 · Cited by 55
Chemotherapy-induced metastasis: molecular mechanisms and clinical therapies
Su, J.-X., Li, S.-J., Zhou, X., Zhang, Z., Yu, Y., Liu, S.-L., & Qi, Q. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01093-8 · Cited by 56
Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels
Sideras, K., de Man, R. A., Harrington, S. M., Polak, W. G., Zhou, G., Schutz, H. M., Pedroza‐González, A., Biermann, K., Mancham, S., Hansen, B. E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47235-z · Cited by 55
Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells
Noh, H., Hu, J., Wang, X., Xia, X., Satelli, A., & Li, S. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0093-y · Cited by 59
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development
Zhu, M. M. T., Dancsok, A. R., & Nielsen, T. O. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0750-1 · Cited by 55
“IDO-1 activation through STimulator of INterferon Genes (STING) and IFN-I signalling is promoted in low-antigenicity tumors, such as native Lewis lung carcinoma, but not in melanoma or Lewis lung carcinomas with enhanced antigenicity [42].”
BackgroundInfluential
Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile
de Groot, R., van Loenen, M. M., Guislain, A., Nicolet, B. P., Heeren, J. J. F., Verhagen, O. J. H. M., van den Heuvel, M. M., de Jong, J., Burger, P., van der Schoot, C. E., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1648170 · Cited by 57
“Indeed, a high correlation with tumor-reactive CD8 T cell infiltrates is observed in murine melanoma models.(48) Irrespective of the mechanism(s) that contribute to the correlation of high Treg numbers with high percentages of tumor-reactive T cells, it is tempting to speculate that patients with high Treg numbers may…”
Background
Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice
Munakata, L., Tanimoto, Y., Osa, A., Meng, J., Haseda, Y., Naito, Y., Machiyama, H., Kumanogoh, A., Omata, D., Maruyama, K., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.09.011 · Cited by 50
Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle
Wattenberg, M. M., & Beatty, G. L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.002 · Cited by 54
Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy
Ye, J., Hou, B., Chen, F., Zhang, S., Xiong, M., Li, T., Xu, Y., Xu, Z., & Yu, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.021 · Cited by 54
Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
Fan, Y., Ma, K., Wang, C., Ning, J., Hu, Y., Dong, D., Dong, X., Geng, Q., Li, E., & Wu, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s115054 · Cited by 54
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
Pu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 56
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer
Doo, D. W., Meza‐Perez, S., Londoño, A. I., Goldsberry, W. N., Katre, A. A., Boone, J. D., Moore, D. J., Hudson, C. T., Betella, I., McCaw, T. R., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920913798 · Cited by 52
Immune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 54
Drug resistance mechanisms in cancers: Execution of pro-survival strategies
Dhanyamraju, P. K. (2023) · Journal of Biomedical Research · doi:10.7555/jbr.37.20230248 · Cited by 56
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy
Chen, T.-W., Huang, K. C., Chiang, S., Chen, W. T., Ke, T., & Chao, K. S. C. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02874-7 · Cited by 53
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Veldman, J., Visser, L., van den Berg, A., & Diepstra, A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101931 · Cited by 53
Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients
Kuo, C., Yang, C., Lin, C., Lin, G., Sytwu, H., & Chen, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111057 · Cited by 52
Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy
Xie, X., Feng, Y., Zhang, H., Su, Q., Song, T., Yang, G., Li, T., Wei, X., Li, T., Qin, X., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.03.008 · Cited by 53
Identification and validation of neurotrophic factor-related genes signature in HNSCC to predict survival and immune landscapes
Peng, G., Chi, H., Gao, X., Zhang, J., Song, G., Xie, X., Su, K., Song, B., Yang, J., Gu, T., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1010044 · Cited by 52
Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment
Lin, Z., Huang, K., Guo, H., Jia, M., Liu, X., 孙秋芹, Chen, X., Wu, J., Yao, Q., Zhang, P., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114567 · Cited by 52
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014
Ascierto, P. A., Atkins, M. B., Bifulco, C. B., Botti, G., Cochran, A. J., Davies, M. A., Demaria, S., Dummer, R., Ferrone, S., Formenti, S. C., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0736-1 · Cited by 53
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
Lonardi, S., Prete, A. A., Morano, F., Messina, M., Formica, V., Corsi, D. C., Orciuolo, C., Frassineti, G. L., Zampino, M. G., Casagrande, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002996 · Cited by 56
“18 The secretion of interferon gamma by NK cells may induce tumor PD-L1 expression, 19 leading to potential synergistic activity between PD-L1 and cetuximab.”
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score
Cho, Y. A., Lee, H., Kim, D. G., Kim, H., Ha, S. Y., Choi, Y., Jang, K., & Kim, K. (2021) · Cancers · doi:10.3390/cancers13184659 · Cited by 52
“Highly mutated tumors are more likely to produce abundant tumorspecific mutant epitopes, which may function as neoantigens [15,20] and upregulates PD-L1 expression [40,41]; however, a large study reported the opposite [34].”
Background
An anti-CTLA-4 heavy chain–only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile
Gan, X., Shan, Q., Li, H., Janssens, R., Shen, Y., He, Y., Chen, F., van Haperen, R., Drabek, D., Li, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200879119 · Cited by 51
Combination Cancer Treatment: Using Engineered DNAzyme Molecular Machines for Dynamic Inter‐ and Intracellular Regulation
Qian, R., Zhou, Z., Wu, Y., Yang, Z., Guo, W., Li, D., & Lu, Y. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202210935 · Cited by 51
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
Mariniello, A., Borgeaud, M., WEINER, M. H., Frisone, D., Kim, F., & Addeo, A. (2025) · BioDrugs · doi:10.1007/s40259-024-00700-2 · Cited by 61
“In a translational prelimi-nary report on six patients treated, one achieved a deep partial response, while in three patients undergoing longitudinal biopsies, tumor remodeling with expanded CD8 + T cells and LAMP3 dendritic cells were observed post-treatment [36 days] [160].”
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Rowdo, F. P. M., Barón, A., Urrutia, M., & Mordoh, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00127 · Cited by 51
Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment
Arina, A., Corrales, L. P., & Bronte, V. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.002 · Cited by 52
Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer
Cohen, I., & Blasberg, R. G. (2017) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223417731565 · Cited by 55
Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors
Chen, C.-L., Pan, Q., Weng, D., Xie, C.-M., Zhao, J.-J., Chen, M.-S., Peng, R.-Q., Li, D., Wang, Y., Tang, Y., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1417721 · Cited by 51
Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma
Poźniak, J., Nsengimana, J., Laye, J. P., O'Shea, S. J., Diaz, J. M. S., Droop, A., Filia, A., Harland, M., Davies, J. R., Mell, T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2864 · Cited by 51
“This is entirely in keeping with previously published observations of increased Treg numbers and accompanying expression of checkpoint molecules as a results of homeostatic mechanisms driven by melanoma infiltrating CD8+ T cells [34].”
Result
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo
Ojha, R., Nepali, K., Chen, C., Chuang, K.-H., Wu, T.-Y., Lin, T. E., Hsu, K., Chao, M., Lai, M.-J., Lin, M.-H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112086 · Cited by 51
Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients
Deng, M., Li, S., Fu, X., Yan, X., Chen, J., Qiu, Y., & Guo, R. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02081-w · Cited by 52
Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis
Zhang, C., Dang, D., Cong, L., Sun, H., & Cong, X. (2021) · Cancer Medicine · doi:10.1002/cam4.3963 · Cited by 50
Immunotherapy-related biomarkers: Confirmations and uncertainties
Catalano, M., Iannone, L. F., Nesi, G., Nobili, S., Mini, E., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104135 · Cited by 61
Ferroptosis: CD8+T cells’ blade to destroy tumor cells or poison for self-destruction
Liang, Y., Zhao, Y., Li, X., Li, X., & Zhao, Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02415-x · Cited by 56
Oncolytic Virus Immunotherapy for Melanoma
Dharmadhikari, N. D., Mehnert, J. M., & Kaufman, H. L. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0326-0 · Cited by 51
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases
Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Smolkin, M. E., Olson, W. C., Deacon, D. H., Smith, K. T., Galeassi, N., Chianese‐Bullock, K. A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1881-y · Cited by 51
Tissue Site and the Cancer Immunity Cycle
Horton, B. L., Fessenden, T. B., & Spranger, S. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.006 · Cited by 50
“has long been a positive prognostic indicator [3], and both pre-clinical and clinical evidence suggests that responsiveness to CBT is strongly associated with the presence of tumorreactive effector T cells within the tumor microenvironment [4, 5].”
Background
The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice
Degoricija, M., Korać-Prlić, J., Vilović, K., Ivanišević, T., Haupt, B. E., Palada, V., Petković, M., Karaman, I., & Terzić, J. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02146-5 · Cited by 47
Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance
Nagy, N. A., de Haas, A. M., Geijtenbeek, T. B. H., van Ree, R., Tas, S. W., van Kooyk, Y., & de Jong, E. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674048 · Cited by 49
Modulation of Siglec-7 Signaling Via In Situ-Created High-Affinity cis -Ligands
Hong, S., Yu, C., Rodrigues, E., Shi, Y., Chen, H., Wang, P., Chapla, D. G., Gao, T., Zhuang, R., Moremen, K. W., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00064 · Cited by 50
An Overview of Endometrial Cancer with Novel Therapeutic Strategies
Kuhn, T. M., Dhanani, S., & Ahmad, S. (2023) · Current Oncology · doi:10.3390/curroncol30090574 · Cited by 49
T Cell Intrinsic USP15 Deficiency Promotes Excessive IFN-γ Production and an Immunosuppressive Tumor Microenvironment in MCA-Induced Fibrosarcoma
Zou, Q., Jin, J., Xiao, Y., Zhou, X., Hu, H., Cheng, X., Kazimi, N., Ullrich, S. E., & Sun, S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.046 · Cited by 49
Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand
Kang, S. W., Lee, S. C., Park, S. H., Kim, J., Kim, H. H., Lee, H., Seo, S. K., Kwon, B. S., Cho, H. R., & Kwon, B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0610 · Cited by 49
T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers
Asaka, S., Yen, T., Wang, T., Shih, I., & Gaillard, S. L. (2018) · Modern Pathology · doi:10.1038/s41379-018-0172-x · Cited by 49
IDO1 Inhibition Overcomes Radiation-Induced “Rebound Immune Suppression” by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Li, A., Barsoumian, H. B., Schoenhals, J. E., Caetano, M. S., Wang, X., Menon, H., Valdecanas, D. R., Niknam, S., Younes, A. I. A., Cortez, M. A., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.03.022 · Cited by 49
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
Yoo, S. H., Keam, B., Ock, C.-Y., Kim, S., Han, B., Kim, J., Lee, K., Jeon, Y. K., Jung, K. C., Chung, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44206-2 · Cited by 49
Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
Economopoulou, P., Kotsantis, I., & Psyrri, A. K. (2020) · Cancers · doi:10.3390/cancers12113377 · Cited by 48
Adoptive T cell therapy: Boosting the immune system to fight cancer
León, E. C., Ranganathan, R., & Savoldo, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101437 · Cited by 48
Non-coding RNAs and macrophage interaction in tumor progression
Entezari, M., Sadrkhanloo, M., Rashidi, M., Asnaf, S. E., Taheriazam, A., Hashemi, M., Ashrafizadeh, M., Zarrabi, A., Rabiee, N., Hushmandi, K., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103680 · Cited by 50
The paradox of radiation and T cells in tumors
Gough, M. J., & Crittenden, M. R. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100808 · Cited by 51
CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
Boumelha, J., de Castro, A., Bah, N. K., Cha, H., Trécesson, S. D. C., Rana, S., Tomaschko, M., Anastasiou, P., Mugarza, E., Moore, C., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2627 · Cited by 51
Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?
Vo, M.-C., Tran, V.-D.-H., Nguyen, V., Ruzimurodov, N., Trung, D. T., Kim, S. K., Jung, S., & Lee, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01744-9 · Cited by 59
“For instance, in melanoma, high programmed death-ligand 1 expression has been associated with CAR-T cell failure, as T cells are rendered dysfunctional in the face of overwhelming immunosuppressive signaling [70].”
Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers
Chiang, S., Huang, K. C., Ke, T., Chen, T.-W., Lan, Y.-C., You, Y., Chen, W. T., & Chao, K. S. C. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2275-0 · Cited by 49
Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
Hammerl, D., Massink, M. P. G., Smid, M., van Deurzen, C. H. M., Meijers-Heijboer, H. E. J., Waisfisz, Q., Debets, R., & Martens, J. W. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0285 · Cited by 46
“Besides TIL scores, we found significant associations with MFS (Hazard 266 Ratio (HR) <1, p<0.05) for the following gene sets: Type-II IFN in BC (not differentiated per subtype), 267 as well as her2 and luminal-B subtypes; co-inhibitory/stimulatory receptors and ligands in BC, as well 268 as basal-like, her2 and lumin…”
BackgroundResultInfluential
Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras
Cohen, M. A., Zhang, S., Sengupta, S., Ma, H., Bell, G. W., Horton, B. L., Sharma, B., George, R. E., Spranger, S., & Jaenisch, R. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.02.001 · Cited by 47
Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity
Yang, A., Li, M. Y., Zhang, Z. H., Wang, J. Y., Xing, Y., Ri, M., Jin, C. H., Xu, G. H., Piao, L. X., Jin, H. L., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113598 · Cited by 48
Localized Multi‐Component Delivery Platform Generates Local and Systemic Anti‐Tumor Immunity
Acharya, A. P., Sinha, M. K., Ratay, M. L., Ding, X., Balmert, S. C., Workman, C. J., Wang, Y., Vignali, D. A. A., & Little, S. R. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201604366 · Cited by 46
Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force
Hatzioannou, A., Alissafi, T., & Verginis, P. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-493r · Cited by 45
PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression
Kraft, S., Fernández‐Figueras, M. T., Richarz, N. A., Flaherty, K. T., & Hoang, M. P. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.05.007 · Cited by 47
Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS
Sugio, T., Miyawaki, K., Kato, K., Sasaki, K., Yamada, K., Iqbal, J., Miyamoto, T., Ohshima, K., Maeda, T., Miyoshi, H., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018018754 · Cited by 47
Immunotherapy for Head and Neck Cancer
Sim, F. W., Leidner, R. S., & Bell, R. B. (2018) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2018.09.002 · Cited by 48
An emerging role for cellular crosstalk in the cancer stem cell niche
Oshimori, N., Guo, Y., & Taniguchi, S. (2021) · The Journal of Pathology · doi:10.1002/path.5655 · Cited by 50
“In addition to PD-L1, T cell-inflamed tumors often exhibit high expressions of other immunosuppressive mediators, such as indoleamine-2,3-dioxygenase (IDO) and FoxP3 Tregs [48].”
Background
Inflammation and Cancer
Todoric, J., Umemura, A., Taniguchi, K., & Karin, M. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm027 · Cited by 46
In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy
Li, J., Luo, G., Zhang, C., Long, S., Guo, L., Yang, G., Wang, F., Zhang, L., Shi, L., Fu, Y., et al. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100238 · Cited by 47

Authors: Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F.
Affiliations: University of Chicago (US)
Corresponding author: Spranger, Stefani
Spaapen, Robbert M.
Gajewski, Thomas F.
ORCID: Spranger, Stefani
Spaapen, Robbert M.
Zha, Yuanyuan
Williams, Jason
Gajewski, Thomas F.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-08-28
Volume: 5
Issue: 200
Pages: 200ra116-200ra116
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.3006504
PMC: PMC4136707
OpenAlex: W2136731993
Cited by: 1,677
References: 50
Citations by year: 2026: 49 · 2025: 76 · 2024: 112 · 2023: 122 · 2022: 136 · 2021: 173 · 2020: 158 · 2019: 162 · 2018: 171 · 2017: 176 · 2016: 155 · 2015: 111 · 2014: 70 · 2013: 6
FWCI: 61.01
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: melanoma, tumor microenvironment, PD-L1, indoleamine 2,3-dioxygenase, regulatory T cells, CD8+ T cells, immunosuppression, immune checkpoint, interferon-gamma, cancer immunotherapy, tumor immune evasion
MeSH terms: Animals, Humans, Interferon-gamma, Lymphocyte Activation, Melanoma, Melanoma, Experimental, Neoplasm Metastasis, Up-Regulation, CD8-Positive T-Lymphocytes, Chemokines, Xenograft Model Antitumor Assays, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks